Our fourth and final daily wrap-up features highlights from the key late breaking trials, and some of the most interesting abstracts presented at the meeting.
Key Late-Breaking Clinical Trials Covered:
• ASCOT Trial – Testing CRP at baseline and on-treatment as an independent predictor of cardiovascular outcomes
• DEFINE Trial – Determining the efficacy and tolerability of CETP inhibition with anacetrapib
• ASSERT Study – Results of the first major clinical trial of an oral agent inducing ApoA-1 synthesis
• SIMPLICITY HTN-2 Study – International, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension
Highlighted in the video is expert commentary from leaders in cardiology including:
• Donald Lloyd-Jones, MD, ScM, FACC, FAHA – Chair of Preventive Medicine, Northwestern University Feinberg School of Medicine
• Christopher P. Cannon, MD – Associate Professor of Medicine, Harvard Medical School
• Eliot A. Brinton, MD, FAHA – Director of the Metabolism Section of Cardiovascular Genetics, University of Utah School of Medicine
• Murray Esler, MD – Associate Professor, Baker Heart Research Institute
• Margaret Fang, MD, MPH – Medical Director, UCSF Anticoagulation Clinic
• John A. Ryan, MD, FACS – Cardiology Fellow, University of Chicago Hospitals
Check back for more in-depth coverage of AHA Scientific Sessions 2010 in the coming days.